Previous 10 | Next 10 |
Deciphera Pharmaceuticals (NASDAQ: DCPH ) announces data from the ovarian cancer cohort in Part 2 of the ongoing Phase 1b/2 study of rebastinib , the selective TIE2 inhibitor, in combination with paclitaxel and from Part 1 of the Phase 1b/2 study of rebastinib in combination with carbop...
- Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer - - Rebastinib Combined with Carboplatin was Well-tolerated in Patients with Metastatic Solid Tumors and Showed Initial C...
- Results Consistent with Those Presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Support Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announ...
COVID-19 Pandemic BioKangtai (SHZ: 300601), a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's (AZN) COVID-19 vaccine in China. The candidate is an adenovirus vector-based COVID-19 vaccine that was created by Oxford University and partnered b...
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Canaccord Genuity 40 th Annual Growth Conference on Thursday, August 13, 2020 at 9:00 AM ET. The conference will be held in a virtual meeting format. ...
The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this Read more ...
Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q2 2020 Earnings Call Aug 4, 2020 , 4:30 p.m. ET Operator Continue reading
Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2020 Earnings Conference Call August 4, 2020, 04:30 PM ET Company Participants Jen Robinson - VP, IR Steve Hoerter - President and CEO Dan Martin - CCO Matt Sherman - CMO Tucker Kelly - CFO Conference Call Participants Chris Ra...
Deciphera Pharmaceuticals (NASDAQ: DCPH ) : Q2 GAAP EPS of -$1.20 beats by $0.17 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- QINLOCK TM Approved for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor and U.S. Commercial Launch Underway - - Reported QINLOCK Net Revenue of $4.8 Million in the First Partial Quarter of Launch - - Company Expects to Complete Enrollment in Phase 3 INTRIGUE Study ...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...